Elisa Fontana

机构：Roche (Switzerland), Universitat Autònoma de Barcelona, Sarah Cannon Research Institute · ORCID：0000-0002-4991-9355

发表论文 280 篇 · 总被引 2152 次 · h-index 21

代表论文

Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study (2026 · Journal of Clinical Oncology)
Pivotal PYNNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a TP53 Y220C mutation: Initial ovarian cancer analysis. (2026 · Journal of Clinical Oncology)
Supplementary Figure S1 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)
Figure 2 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)
Supplementary Figure S10 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)
Supplementary Figure S14 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer (2026)